EE04581B1 - a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis - Google Patents

a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Info

Publication number: EE04581B1
Authority: EE; Estonia
Prior art keywords: alpha; inhibitors; integrin receptor; beta; treatment
Prior art date: 1998-05-22

Application number

EEP200000685A

Other languages

English (en)

Estonian (et)

Inventor

Cosgrove Dominic

Original Assignee

Boys Town National Research Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-22

Filing date

1999-05-19

Publication date

2006-02-15

1999-05-19 Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital

2002-04-15 Publication of EE200000685A publication Critical patent/EE200000685A/xx

2006-02-15 Publication of EE04581B1 publication Critical patent/EE04581B1/xx

Links

108010055795 Integrin alpha1beta1 Proteins 0.000 title abstract 3
208000017169 kidney disease Diseases 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 2
108091006082 receptor inhibitors Proteins 0.000 title abstract 2
102000008186 Collagen Human genes 0.000 abstract 2
108010035532 Collagen Proteins 0.000 abstract 2
229920001436 collagen Polymers 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
210000000585 glomerular basement membrane Anatomy 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
238000010172 mouse model Methods 0.000 abstract 1
201000002793 renal fibrosis Diseases 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Combustion & Propulsion (AREA)
Materials Engineering (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200000685A 1998-05-22 1999-05-19 a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis EE04581B1 (et)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US8658798P	1998-05-22	1998-05-22
US8876698A	1998-06-02	1998-06-02
US15048598A	1998-09-09	1998-09-09
PCT/US1999/011073 WO1999061040A2 (en)	1998-05-22	1999-05-19	USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number	Publication Date
EE200000685A EE200000685A (et)	2002-04-15
EE04581B1 true EE04581B1 (et)	2006-02-15

Family

ID=56289911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000685A EE04581B1 (et)	1998-05-22	1999-05-19	a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Country Status (21)

Country	Link
EP (1)	EP1079843B1 (xx)
JP (1)	JP2002516287A (xx)
CN (1)	CN1187084C (xx)
AT (1)	ATE359804T1 (xx)
BR (1)	BR9911067A (xx)
CA (1)	CA2329757C (xx)
CZ (1)	CZ296262B6 (xx)
DE (1)	DE69935853T2 (xx)
DK (1)	DK1079843T3 (xx)
EA (1)	EA004145B1 (xx)
EE (1)	EE04581B1 (xx)
ES (1)	ES2285841T3 (xx)
HU (1)	HUP0202048A3 (xx)
NO (1)	NO20005883L (xx)
NZ (1)	NZ508317A (xx)
PL (1)	PL345946A1 (xx)
PT (1)	PT1079843E (xx)
SG (1)	SG117434A1 (xx)
SI (1)	SI1079843T1 (xx)
TR (1)	TR200003432T2 (xx)
WO (1)	WO1999061040A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK17232001A3 (sk)	1999-06-01	2002-09-10	Biogen, Inc.	Použitie blokujúcej monoklonálnej protilátky proti VLA-1 na výrobu farmaceutickej kompozície na liečenie zápalových ochorení
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
JP4975922B2 (ja) *	1999-09-14	2012-07-11	バイオジェン・アイデック・エムエイ・インコーポレイテッド	１つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
JP2004502644A (ja) *	2000-03-09	2004-01-29	ジェンザイム、コーポレーション	腎機能の喪失を治療または予防するためのＴＧＦ−β拮抗薬の使用
YU80903A (sh)	2001-04-13	2006-05-25	Biogen Inc.	Antitela vla-1
CN1826137A (zh)	2002-11-01	2006-08-30	博伊斯镇国家研究医院	α1β1整联蛋白的可诱导的配体和用途
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
CA2652815C (en)	2006-05-25	2015-12-15	Biogen Idec Ma Inc.	Methods of treating stroke
GB0911888D0 (en) *	2009-07-08	2009-08-19	Oxford Biodynamics Ltd	Method of treating age related disorders
UA115652C2 (uk)	2011-04-25	2017-12-11	Реґюлус Терап'Ютікс Інк.	Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
US10316095B2 (en)	2012-02-16	2019-06-11	Santarus, Inc.	Antibody formulations
MY173600A (en)	2012-04-25	2020-02-08	Sanofi Sa	Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) *	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта
CN104450726A (zh) *	2013-09-17	2015-03-25	深圳华大基因科技有限公司	Col4a5基因突变体及其应用
CN104212806B (zh) *	2014-07-21	2017-05-17	深圳华大基因股份有限公司	Alport综合征新的突变致病基因及其编码蛋白和应用
US20230374141A1 (en) *	2020-10-05	2023-11-23	Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital	Combination therapy for alport renal disease
CN112575074B (zh) *	2020-10-09	2022-12-27	中山大学	Nestin基因及蛋白在治疗器官纤维化中的应用
JPWO2023085396A1 (xx) *	2021-11-12	2023-05-19
CN114698592B (zh) *	2022-04-29	2022-11-04	中国医学科学院北京协和医院	一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9519667D0 (en) *	1995-09-27	1995-11-29	Univ Manchester	Pharmaceutical composition

1999
- 1999-05-19 DE DE69935853T patent/DE69935853T2/de not_active Expired - Lifetime
- 1999-05-19 JP JP2000550500A patent/JP2002516287A/ja active Pending
- 1999-05-19 HU HU0202048A patent/HUP0202048A3/hu unknown
- 1999-05-19 EE EEP200000685A patent/EE04581B1/xx not_active IP Right Cessation
- 1999-05-19 AT AT99923224T patent/ATE359804T1/de not_active IP Right Cessation
- 1999-05-19 EA EA200001092A patent/EA004145B1/ru not_active IP Right Cessation
- 1999-05-19 WO PCT/US1999/011073 patent/WO1999061040A2/en not_active Ceased
- 1999-05-19 CA CA2329757A patent/CA2329757C/en not_active Expired - Fee Related
- 1999-05-19 NZ NZ508317A patent/NZ508317A/en unknown
- 1999-05-19 ES ES99923224T patent/ES2285841T3/es not_active Expired - Lifetime
- 1999-05-19 CZ CZ20004358A patent/CZ296262B6/cs not_active IP Right Cessation
- 1999-05-19 CN CNB998090247A patent/CN1187084C/zh not_active Expired - Fee Related
- 1999-05-19 PL PL99345946A patent/PL345946A1/xx unknown
- 1999-05-19 BR BR9911067-9A patent/BR9911067A/pt not_active IP Right Cessation
- 1999-05-19 DK DK99923224T patent/DK1079843T3/da active
- 1999-05-19 SI SI9930967T patent/SI1079843T1/sl unknown
- 1999-05-19 PT PT99923224T patent/PT1079843E/pt unknown
- 1999-05-19 TR TR2000/03432T patent/TR200003432T2/xx unknown
- 1999-05-19 SG SG200300701A patent/SG117434A1/en unknown
- 1999-05-19 EP EP99923224A patent/EP1079843B1/en not_active Expired - Lifetime
2000
- 2000-11-21 NO NO20005883A patent/NO20005883L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ508317A (en)	2004-01-30
CA2329757A1 (en)	1999-12-02
CZ20004358A3 (cs)	2002-01-16
CA2329757C (en)	2013-11-19
CN1310625A (zh)	2001-08-29
ES2285841T3 (es)	2007-11-16
DE69935853T2 (de)	2008-01-10
WO1999061040A9 (en)	2001-02-01
JP2002516287A (ja)	2002-06-04
BR9911067A (pt)	2001-02-06
DE69935853D1 (de)	2007-05-31
DK1079843T3 (da)	2007-07-30
EA004145B1 (ru)	2004-02-26
PL345946A1 (en)	2002-01-14
NO20005883D0 (no)	2000-11-21
WO1999061040A3 (en)	2000-01-27
HUP0202048A2 (en)	2002-10-28
HUP0202048A3 (en)	2006-11-28
EP1079843B1 (en)	2007-04-18
ATE359804T1 (de)	2007-05-15
EE200000685A (et)	2002-04-15
SI1079843T1 (sl)	2007-10-31
CZ296262B6 (cs)	2006-02-15
EP1079843A2 (en)	2001-03-07
EA200001092A1 (ru)	2001-06-25
WO1999061040A2 (en)	1999-12-02
PT1079843E (pt)	2007-06-26
CN1187084C (zh)	2005-02-02
NO20005883L (no)	2001-01-17
TR200003432T2 (tr)	2001-03-21
SG117434A1 (en)	2005-12-29

Publication	Publication Date	Title
EE04581B1 (et)	2006-02-15	a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
IL143901A0 (en)	2002-04-21	Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
BR0014078A (pt)	2002-12-31	Inibidores de fator xa
ES2235353T3 (es)	2005-07-01	Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
TR200103233T2 (tr)	2002-04-22	Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
AU5338301A (en)	2001-10-30	Methods and compositions for modulating alpha adrenergic receptor activity
BR0013219A (pt)	2002-04-23	Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
TR200000756T2 (tr)	2000-09-21	Davranış bozukluğu tedavisi.
BG105112A (bg)	2001-10-31	Средство с антидепресивно действие
AR049829A1 (es)	2006-09-06	Procedimiento y composiciones utiles para prevenir y/o tratar las pieles sensibles y/o secas
HUP0104688A2 (hu)	2002-03-28	Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
NO992282L (no)	1999-05-11	Benzonaftyridiner som bronkialterapentika
ATE234812T1 (de)	2003-04-15	Integrin antagonisten
WO2001078703A3 (en)	2002-03-21	Methods and compositions for modulating alpha adrenergic receptor activity
ES2216630T3 (es)	2004-10-16	Metodos de tratar la hipertension dependiente de la sal.
BRPI0415896A (pt)	2007-01-09	combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
DK0946157T3 (da)	2002-07-08	Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
MY136261A (en)	2008-09-30	Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
BRPI0414724A (pt)	2006-11-21	combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
YU39598A (sh)	1999-09-27	Upotreba duloksetina i njegova farmaceutska smeša
DK1152757T3 (da)	2005-10-31	MMP-inhibitorer i bindevævsblödhed
DE50111407D1 (de)	2006-12-21	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK0841937T4 (da)	2009-05-11	Anvendelse af betaglycan til reduktion af ardannelse
DE60009315D1 (de)	2004-05-13	Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date	Code	Title	Description
2005-10-17	HC1A	Change of owner name
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20090519